Braxia Scientific Secures Approval for Direct Billing Insurance on Ketamine Treatments for Veterans Affairs Canada Clients

Shares :

Braxia Scientific Corp. Logo (CNW Group/Braxia Scientific Corp.)

TORONTO, July 20, 2021 /CNW Telbec/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce that it has established direct billing practices with health insurance provider Medavie Blue Cross for qualifying Canadian military veterans. The foregoing development will allow for 100% coverage of oral, nasal spray and intravenous ketamine treatments, plus travel costs, delivered at the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned subsidiary of Braxia.

This support from Blue Cross will allow members of the Canadian Armed Forces and Royal Canadian Mounted Police (RCMP), as well as their family members, to receive fully funded treatment without any concern over out-of-pocket expenses.

BREAKING : Majic Acquires The $150M Calfin Global Crypto Exchange: CGCX | READ HERE

“We are grateful for this insurance coverage, which has facilitated access for Canadian veterans to receive this important treatment,” said Dr. Roger McIntyre, CEO, Braxia Scientific Corp., noting that the clinics have already seen an increase in bookings. “Many veterans struggle with depression, PTSD and suicidal thoughts. Unfortunately, conventional treatments are often ineffective or only partially effective in persons who live with these conditions, leaving many suffering with persistent symptoms and impaired function.”

The Canadian veteran population numbers an estimated 629,300,1 while the RCMP employs nearly 30,200 people.2 Veterans Affairs Canada served more than 187,100 clients between 2019-20.3 According to government statistics, nearly 16% of full-time Canadian Armed Forces personnel experience depression at some point in their lives, while more than 11% reported symptoms of post-traumatic stress disorder (PTSD)4.

Braxia’s Chief Medical and Scientific Officer, and CRTCE Medical Director, Dr. Josh Rosenblat, commented, “As we provide ketamine treatments for this population, we are also carefully collecting outcome data to help refine treatment protocols and quantitatively determine the real-world effectiveness of ketamine and related treatments in this population. We are specifically tracking symptoms of depression, anxiety, suicidality and PTSD. We have seen some promising benefits for many veterans that have received this novel treatment in our clinic and plan to publish our findings in the coming months.”

Dr. McIntyre added, “The presentation of depression in patients with comorbid PTSD and trauma is often quite different from that seen in the general population insofar as it is often more severe, chronic and not sufficiently responsive to conventional treatment approaches. In contradistinction, our experience at CRTCE, along with the published scientific literature, suggests that persons with depression and history of trauma and/or PTSD have a very reasonable chance of benefit from receiving ketamine treatment.”

“A related, but different priority, is reduction of suicide in the general population, especially in populations at-risk, which would include, but not be limited to, members of the Canadian Armed Forces and RCMP. Current evidence indicates that ketamine is capable of rapid and significant attenuation of suicidality in persons affected by depression and represents an important treatment avenue for persons with suicidal thoughts and behaviour.”


About Braxia Scientific Corp.

Braxia Scientific, is a medical research Company with clinics that provide innovative ketamine treatments for persons with depression and related disorders. Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia is primarily focused on (i) owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. Braxia develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., Braxia currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :